연구성과로 돌아가기
JCR 2024 저널 목록 (1328 / 2104)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Journal Name | Publisher | ISSN | eISSN | Edition | WoS Category | Total Citation | JIF | JIF Quartile | 상위 JCR(%) | JIF % | JIF Rank | 5-Year JIF | 5-Year Quartile | JIF w/o Self-Cites | Immediacy Index | JCI | JCI Rank | JCI Quartile | JCI Percentile | Eigenfactor Score | Normalized Eigenfactor | Article Influence Score | AIS Quartile | Citable Items | Articles in Citable Items (%) | Cited Half-Life | Citing Half-Life | Total Articles | Citable OA (%) | 수집시기 | 바로가기 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BIOMETRICAL JOURNAL | WILEY | 0323-3847 | 1521-4036 | SCIE | MATHEMATICAL & COMPUTATIONAL BIOLOGY | 4,655 | 1.8 | Q3 | 67.9 | 32.1 | 46/67 | 2.0 | Q3 | 1.7 | 0.4 | 0.62 | 35/67 | Q3 | 48.51 | 0.005 | 1.009 | 1.091 | Q2 | 90 | 94.4% | 16.0 | 11.2 | 85 | 49.8% | 2025-08-05 16:03:59 | 바로가기 |
| Business Management and Economics Engineering | VILNIUS GEDIMINAS TECH UNIV | 2669-2481 | 2669-249X | ESCI | BUSINESS | 108 | 1.6 | Q3 | 67.9 | 32.1 | 215/316 | 1.5 | Q4 | 1.6 | 0.3 | 0.34 | 227/317 | Q3 | 28.55 | 0.000 | 0.017 | 0.159 | Q4 | 21 | 100.0% | 2.7 | 5.3 | 21 | 100.0% | 2025-08-05 16:02:36 | 바로가기 |
| Clinical Parkinsonism & Related Disorders | ELSEVIER | N/A | 2590-1125 | ESCI | CLINICAL NEUROLOGY | 447 | 1.8 | Q3 | 67.9 | 32.1 | 194/285 | 2.2 | Q3 | 1.8 | 0.3 | 0.55 | 196/285 | Q3 | 31.40 | 0.001 | 0.242 | 0.713 | Q3 | 50 | 82.0% | 3.4 | 8.4 | 41 | 100.0% | 2025-08-05 16:02:43 | 바로가기 |
| CORPORATE REPUTATION REVIEW | PALGRAVE MACMILLAN LTD | 1363-3589 | 1479-1889 | ESCI | BUSINESS | 1,316 | 1.6 | Q3 | 67.9 | 32.1 | 215/316 | 2.4 | Q3 | 1.2 | 0.3 | 0.34 | 227/317 | Q3 | 28.55 | 0.000 | 0.080 | 0.411 | Q3 | 32 | 100.0% | 16.1 | 9.3 | 32 | 29.0% | 2025-08-05 16:02:36 | 바로가기 |
| Current Treatment Options in Allergy | SPRINGERNATURE | N/A | 2196-3053 | ESCI | ALLERGY | 299 | 1.7 | Q3 | 67.9 | 32.1 | 27/39 | 1.3 | Q4 | 1.7 | 0.2 | 0.43 | 26/39 | Q3 | 34.62 | 0.000 | 0.094 | 0.338 | Q4 | 20 | 0.0% | 4.1 | 6.9 | 0 | 25.3% | 2025-08-05 16:02:26 | 바로가기 |
| Current Treatment Options in Neurology | CURRENT MEDICINE GROUP | 1092-8480 | 1534-3138 | SCIE | CLINICAL NEUROLOGY | 1,585 | 1.8 | Q3 | 67.9 | 32.1 | 194/285 | 2.4 | Q3 | 1.7 | 0.3 | 0.34 | 240/285 | Q4 | 15.96 | 0.001 | 0.288 | 0.755 | Q3 | 31 | 0.0% | 7.9 | 7.1 | 0 | 16.8% | 2025-08-05 16:02:42 | 바로가기 |
| DIFFERENTIATION | ELSEVIER SCI LTD | 0301-4681 | 1432-0436 | SCIE | CELL BIOLOGY | 2,319 | 2.6 | Q3 | 67.9 | 32.1 | 139/204 | 2.6 | Q3 | 2.5 | 0.8 | 0.58 | 120/204 | Q3 | 41.42 | 0.001 | 0.200 | 0.685 | Q3 | 38 | 94.7% | 13.2 | 13.1 | 36 | 24.3% | 2025-08-05 16:02:38 | 바로가기 |
| DNA AND CELL BIOLOGY | MARY ANN LIEBERT, INC | 1044-5498 | 1557-7430 | SCIE | CELL BIOLOGY | 3,871 | 2.6 | Q3 | 67.9 | 32.1 | 139/204 | 2.4 | Q4 | 2.6 | 0.5 | 0.51 | 139/204 | Q3 | 32.11 | 0.003 | 0.614 | 0.504 | Q4 | 62 | 83.9% | 7.0 | 6.7 | 52 | 3.1% | 2025-08-05 16:02:38 | 바로가기 |
| European Journal of Obstetrics & Gynecology and Reproductive Biology | ELSEVIER | 0301-2115 | 1872-7654 | SCIE | REPRODUCTIVE BIOLOGY | 13,958 | 1.9 | Q3 | 67.9 | 32.1 | 29/42 | 2.3 | Q3 | 1.8 | 0.4 | 0.67 | 26/42 | Q3 | 39.29 | 0.012 | 2.602 | 0.675 | Q3 | 509 | 79.8% | 8.2 | 7.7 | 406 | 23.0% | 2025-08-05 16:05:09 | 바로가기 |
| Health Marketing Quarterly | TAYLOR & FRANCIS LTD | 0735-9683 | 1545-0864 | ESCI | BUSINESS | 430 | 1.6 | Q3 | 67.9 | 32.1 | 215/316 | N/A | N/A | 1.2 | 0.6 | 0.62 | 153/317 | Q2 | 51.89 | 0.000 | 0.044 | N/A | N/A | 25 | 100.0% | 9.6 | 6.9 | 25 | 16.4% | 2025-08-05 16:02:36 | 바로가기 |
| Hematology | TAYLOR & FRANCIS LTD | 1024-5332 | 1607-8454 | SCIE | HEMATOLOGY | 2,294 | 1.6 | Q3 | 67.9 | 32.1 | 67/98 | 1.7 | Q3 | 1.6 | 0.3 | 0.45 | 59/99 | Q3 | 40.91 | 0.002 | 0.477 | 0.423 | Q3 | 163 | 87.7% | 6.1 | 6.9 | 143 | 98.2% | 2025-08-05 16:03:26 | 바로가기 |
| Hematology Transfusion and Cell Therapy | ELSEVIER | 2531-1379 | 2531-1379 | ESCI | HEMATOLOGY | 776 | 1.6 | Q3 | 67.9 | 32.1 | 67/98 | 1.7 | Q3 | 1.6 | 0.4 | 0.36 | 72/99 | Q3 | 27.78 | 0.001 | 0.271 | 0.414 | Q4 | 177 | 91.0% | 3.2 | 8.7 | 161 | 99.4% | 2025-08-05 16:03:26 | 바로가기 |
| IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL | SPRINGER | 1071-2690 | 1543-706X | SCIE | DEVELOPMENTAL BIOLOGY | 2,625 | 1.7 | Q3 | 67.9 | 32.1 | 27/39 | 1.9 | Q4 | 1.6 | 0.4 | 0.41 | 31/39 | Q4 | 21.79 | 0.001 | 0.293 | 0.367 | Q4 | 126 | 92.9% | 8.5 | 8.4 | 117 | 16.0% | 2025-08-05 16:02:51 | 바로가기 |
| Inorganic and Nano-Metal Chemistry | TAYLOR & FRANCIS INC | 2470-1556 | 2470-1564 | SCIE | CHEMISTRY, INORGANIC & NUCLEAR | 1,873 | 1.6 | Q3 | 67.9 | 32.1 | 29/42 | 1.7 | Q3 | 1.6 | 0.3 | 0.28 | 36/43 | Q4 | 17.44 | 0.001 | 0.304 | 0.187 | Q4 | 59 | 93.2% | 4.3 | 7.4 | 55 | 0.3% | 2025-08-05 16:02:39 | 바로가기 |
| International Archives of Otorhinolaryngology | GEORG THIEME VERLAG KG | 1809-9777 | 1809-4864 | ESCI | OTORHINOLARYNGOLOGY | 1,301 | 1.1 | Q3 | 67.9 | 32.1 | 46/67 | 1.4 | Q3 | 1.1 | 0.3 | 0.55 | 48/67 | Q3 | 29.10 | 0.001 | 0.302 | 0.371 | Q3 | 75 | 93.3% | 5.9 | 10.2 | 70 | 100.0% | 2025-08-05 16:04:29 | 바로가기 |
페이지 이동: